Private company
THC Therapeutics, Inc.
THC Therapeutics, Inc. is a farm machinery and equipment company based in Las Vegas.1
Last updated Oct 21, 2026.
Overview
- IndustryFarm Machinery & Equipment1
- HeadquartersLas Vegas, Nevada1
- Business address11700 W Charleston Blvd #73, Las Vegas, Nv 891352
- Filer categoryNon-accelerated filer, Smaller reporting company2
See how the biggest companies compare on our leaderboards
The Company is focused on developing a sanitizing herb dryer, the dHydronator®, which has been specifically designed for the drying and sanitizing (i.e., reducing the bacterial count) of freshly harvested cannabis, and other herbs, flowers, and tea leaves. Additionally, the Company is looking for acquisition candidates and strategic opportunities across the cannabis industry.3 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Financial statements
| Fiscal year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Revenue | $04 | $05 | $06 | $07 | $08 | $08 | |
| Cost of revenue | $04 | $05 | $06 | $07 | $08 | $08 | |
| Gross profit | $04 | $05 | $06 | $07 | $08 | $08 | |
| Selling, general and admin | $213.0K6 | $138.3K6 | |||||
| Operating expenses | $1.7M7 | $493.9K8 | $542.0K8 | ||||
| Operating income | -$6.0M9 | -$26.7M4 | -$1.4M5 | -$940.0K6 | -$1.7M7 | -$493.9K8 | -$542.0K8 |
| Interest | -$101.7K9 | $303.6K4 | $487.7K5 | $551.8K6 | $100.4K7 | $79.6K8 | $144.1K8 |
| Income tax | $7.7M5 | $8.0M6 | $8.1M7 | $8.2M8 | |||
| Net income | -$6.1M9 | -$23.3M4 | -$1.9M5 | -$1.9M6 | -$1.5M7 | -$387.0K8 | -$811.6K8 |
| Earnings per share | -$1.744 | -$0.125 | -$0.086 | -$0.056 | -$0.018 | -$0.028 | |
| Shares (weighted, basic) | 33.2M shares6 | 32.8M shares8 | 35.7M shares8 |
| Fiscal year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Cash | $3.0K4 | $317.6K5 | $43.2K5 | $296.1K6 | $326 | $108 | $358 |
| Inventory | $257 | $07 | |||||
| Current assets | $3.0K9 | $457.8K4 | $43.2K5 | $301.5K6 | $40.7K7 | $9808 | $358 |
| Property, plant and equipment | $07 | $07 | |||||
| Intangible assets | $13.4K7 | $12.0K7 | $10.6K8 | ||||
| Total assets | $2.5M9 | $520.0K4 | $85.3K5 | $480.1K6 | $206.9K7 | $13.0K8 | $10.6K8 |
| Current liabilities | $581.4K9 | $1.3M4 | $1.8M5 | $2.9M6 | $3.2M7 | $3.3M8 | $3.8M8 |
| Total liabilities | $581.4K9 | $1.3M4 | $1.8M5 | $2.9M6 | $3.2M7 | $3.3M8 | $3.8M8 |
| Retained earnings | -$38.0M7 | -$38.4M8 | -$39.2M8 | ||||
| Shareholders’ equity | $1.9M4 | -$749.4K5 | -$1.7M6 | -$2.5M7 | -$3.1M8 | -$3.3M8 | -$3.8M8 |
| Shares outstanding | 13.0M shares9 | 14.8M shares9 | 22.2M shares4 | 29.3M shares6 | 34.1M shares6 | 34.1M shares8 | 40.3M shares8 |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
| Fiscal year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Cash from operations | -$190.2K9 | -$329.8K4 | -$587.9K5 | -$388.5K6 | -$418.9K7 | -$85.4K8 | -$183.3K8 |
| Depreciation and amortization | $12.3K7 | $1.4K8 | $1.4K8 | ||||
| Stock-based compensation | $836.8K7 | $87.2K8 | $222.0K8 | ||||
| Cash from investing | $07 | $07 | |||||
| Share buybacks | $06 | $97.5K7 | $07 | ||||
| Cash from financing | $122.8K7 | $85.4K8 | $183.3K8 |
What it owns
What THC Therapeutics, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
Investments
Intangibles and goodwill
| Item | Latest | A year before | Change |
|---|---|---|---|
| Accumulated amortization | $25.5K8 Jul 31, 2024 | $24.1K8 Jul 31, 2023 | +5.8% |
| Finite-lived intangibles, net | $10.6K8 Jul 31, 2024 | $12.0K8 Jul 31, 2023 | −11.6% |
Properties, in its own words
The Company does not own any real property.
Item 2 of the 10-K filed Feb 27, 2026.3
Leadership
Who has led THC Therapeutics, Inc., and when. Pick a name to see everywhere that person has worked.
- Chief executive officerJamie Mann Nov 8, 2013 to Nov 8, 201312
- Chief executive officerEden Ho Jul 16, 2010 to Jul 16, 201013
- Chief financial officerJamie Mann Nov 8, 2013 to Nov 8, 201312
Board members and other officers (4)
- Vice PresidentHiro Tanaka Nov 14, 2013 to Nov 14, 201314
- Board memberJamie Mann Nov 8, 2013 to Nov 8, 201312
- Board memberHiro Tanaka Nov 14, 2013 to Nov 14, 201314
- Board memberEden Ho Jul 16, 2010 to Jul 16, 201013
Former names
Timeline
- Jul 17, 20258-K Entered a material agreement; Completed an acquisition or sale; Unregistered sale of shares15
- Jun 27, 20258-K Entered a material agreement; Completed an acquisition or sale; Unregistered sale of shares16
- Apr 17, 20258-K Executive or director change17
- Apr 9, 20258-K Executive or director change18
- Mar 27, 20248-K Change of auditor19
- Mar 14, 20248-K Change of auditor20
- Oct 6, 20238-K Unregistered sale of shares; Change in control; Executive or director change21
- Mar 4, 20228-K Change of auditor22
- Jan 3, 20228-K Entered a material agreement; Unregistered sale of shares23
- Nov 8, 20218-K Executive or director change24
- Nov 8, 2013New chief executive Jamie Mann becomes CEO12
- Jul 16, 2010New chief executive Eden Ho becomes CEO13
Filings
27 filings to the SEC since October 2021: 4 annual reports, 9 quarterly reports, 10 major events, 4 other. The latest 20:
- Feb 27, 202610-K EDGAR
- Jul 17, 20258-K EDGAR
- Jun 27, 20258-K EDGAR
- Apr 17, 20258-K/A EDGAR
- Apr 9, 20258-K EDGAR
- Nov 13, 202410-Q EDGAR
- Oct 30, 2024NT 10-K EDGAR
- Sep 5, 202410-Q EDGAR
- Aug 9, 202410-Q EDGAR
- Mar 27, 20248-K/A EDGAR
- Mar 14, 20248-K EDGAR
- Feb 26, 202410-K EDGAR
- Jan 9, 202410-Q EDGAR
- Jan 8, 202410-Q EDGAR
- Oct 6, 20238-K EDGAR
- Dec 22, 202210-Q EDGAR
- Dec 15, 2022NT 10-Q EDGAR
- Nov 25, 202210-K EDGAR
- Nov 1, 2022NT 10-K EDGAR
- Jun 16, 202210-Q EDGAR
The 27 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
SEC filer profile
How THC Therapeutics, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
- Name on EDGARTHC Therapeutics, Inc.1
- CIK0001404935
- Employer ID (EIN)26-01649813
- Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; not a shell company3
- Incorporated inNevada3
- Fiscal year endsJuly 311
- Industry code (SIC)3523 Farm Machinery & Equipment1
- SEC reviewing officeOffice of Technology, Division of Corporation Finance1
- Business address11700 W Charleston Blvd #73, Las Vegas, NV 891351
- Phone833-420-84281
- Shares outstanding40,266,149 shares as of Feb 10, 20263
- Public float$102.2K as of Jan 31, 20243
- AuditorGreenGrowth CPA’s, Los Angeles, California PCAOB ID 65803
- On EDGAR sinceJun 22, 20071
- Filings164 in all: 10-Q (37), 8-K (36), NT 10-Q (15), 10-K (12), UPLOAD (12), NT 10-K (10), 10-12G/A (6), CORRESP (6)1
All 25 form types
8-K/A (5), 3 (4), S-8 (3), 10QSB (2), D (2), EFFECT (2), SC 13G (2), 10-12G (1), 10-K/A (1), 144 (1), 15-15D (1), 4 (1), 424B3 (1), POS AM (1), REGDEX (1), SB-2 (1), SB-2/A (1)
- Latest filingsAnnual report (10-K) Feb 27, 2026
Quarterly report (10-Q) Nov 13, 2024
Latest 8-K (8-K) Jul 17, 2025
Risk factors and legal proceedings
The risks THC Therapeutics, Inc. names in Item 1A of its 10-K filed Feb 27, 2026: 22 risks under these headings, as written.3
- There are numerous and varied risks, known and unknown, that may prevent us from achieving our goals. If any of these risks actually occur, our business, financial condition or results of operation may be materially adversely affected. In such case, the trading price of our common stock could decline, and investors could lose all or part of their investment.
- There is substantial doubt about our ability to continue as a going concern.
- We have had a history of losses and may incur future losses, which may prevent us from attaining profitability.
- Federal drug regulation and enforcement may adversely impact our operations.
- Our products may become subject to regulation by the FDA, which would materially increase the costs associated with developing the products.
- We may not be able to achieve our strategic initiatives and grow our business as anticipated.
- We have a history of changing and discontinuing operations and have retained obligations associated with discontinued activities.
- If we fail to protect our intellectual property, then our ability to compete could be negatively affected, which would harm our financial condition and operating results.
- If our intellectual property is not adequate to provide us with a competitive advantage or to prevent competitors from replicating our products, or if we infringe the intellectual property rights of others, then our financial condition and operating results would be harmed.
- Our products may be subject to recalls.
- Our future success depends on our ability to retain our chief executive officer and other key executives and to attract, retain and motivate qualified personnel.
- We will need additional funding if we intend on executing our operational plans and making future acquisitions. If we are unable to raise capital when needed, we would be forced to delay, reduce or eliminate our planned development.
The other 10 risks
- Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or other assets.
- Our common stock is subject to the SEC’s penny stock rules, which may make it difficult for broker-dealers to complete customer transactions and could adversely affect trading activity in our securities.
- The market price of our common stock may be volatile and may fluctuate in a way that is disproportionate to our operating performance.
- We currently have outstanding shares of preferred stock that have special rights that could limit our ability to undertake corporate transactions, inhibit potential changes of control and reduce the proceeds available to our common stockholders in the event of a change in control.
- We have never paid and do not intend to pay cash dividends.
- Our executive officer and director have the ability to control all matters submitted to stockholders for approval.
- Provisions in our articles of incorporation and by-laws and under Nevada law could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management.
- We will incur increased costs as a result of operating as a public reporting company, and our management will be required to devote substantial time to new compliance initiatives.
- We currently have outstanding, and we may, in the future, issue instruments which are convertible into shares of common stock, which will result in additional dilution to you.
- We cannot predict every event and circumstance that may impact our business and, therefore, the risks discussed herein may not be the only ones you should consider.
Legal proceedings
From time to time, we may become involved in various lawsuits and legal proceedings which arise in the ordinary course of business. However, litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm our business. We are not presently a party to any material litigation, nor to the knowledge of management is any litigation threatened against us, which may materially affect us, other than as set forth herein.
The opening of Item 3, Legal Proceedings.3
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12SEC EDGARJamie Mann, Chief executive officer
- 13SEC EDGAREden Ho, Chief executive officer
- 14SEC EDGARHiro Tanaka, Vice President
- 15
- 16
- 17SEC EDGARExecutive or director change
- 18SEC EDGARExecutive or director change
- 19SEC EDGARChange of auditor
- 20SEC EDGARChange of auditor
- 21
- 22SEC EDGARChange of auditor
- 23
- 24SEC EDGARExecutive or director change